DRDx to Drdx Home

Field of activity

The first field of activity of DRDx is Rheumatoid Arthritis (RA). RA is the most common autoimmune disorder in the word. The treatment of RA patients with TNF-alpha blockers (TBAs) amounts to several billion US$ per annum. The TBA market is currently led by three products of well-know pharmaceutical companies. The market will be facing significant changes due to the expiry of patent protection and the entry of biosimilars as well as as medications with other modes of action. DRDx`s test kit allows to classify RA patients as responder or non-responder to TBAs.
As a consequence, RA patients not susceptible to therapy with TBAs can be administered at an early stage to other therapeutic options. This reduces the negative influence of side effects and leads to significant improvement and preservation of the health condition of RA patients.

Drug Response Dx has been founded by a team of experts in the field of molecular biology and autoimmunity at the interface of in vitro diagnostics (IVD) and therapy.
After several years of collaboration, the team has developed a biomarker set, which qualifies as Companion Diagnostics in the field of RA. The goal of DRDx is the technical and clinical validation of an IVD test kit for the reliable prediction of therapy response to TBAs ahead of treatment. The test will allow the stratification of patients with high confidence and resolves an urgent medical need within RA. The IP has been generated by the co-founders of DRDx. The biomarker set has been exclusively licensed to DRDx.

News – Press – Events

29. January, 2014

Drug Response Dx GmbH is presenting at the Theragnostics-Workshop of the High-Tech Partnering Conference


27. – 30. January, 2014

The Drug Response Dx GmbH is represented on the Arab Health 2014 at the Dubai


11. December, 2013

Drug Response Dx GmbH has been certified